Full Press Release Details
FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome.
BBIO
FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome
Key Takeaway: FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome